Condition: Hepatocellular Carcinoma · Transcatheter Arterial Chemoembolization · Anti-PD1 Antibody · Sponsor: Sun Yat-sen University
Hepatocellular carcinoma (HCC) with spontaneous rupture is a potentially fatal complication and usually has poor prognosis. In most conditions, the tumors could not be radically moved. Then minimally therapy like transcatheter arterial chemoembolization (TACE) could effectively stanch the ruptured tumor and bleeding vessels. Then TACE combined the Lenvatinib and PD-1 inhibitor for this subtype HCC could effectively inhibit the tumor and improve the prognosis.
This description comes directly from the study's public registry record.
Qunfang Zhou, MD · 86 19868000115 · zhouqun988509@163.com
Mingyu Liu, MD · 15626040233 · go1984liu@163.com
Always discuss trial participation with your own doctor first.
| Qunfang Zhou | Beijing, None Selected, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06740370